Abstract:Background: The differential diagnosis of α-synucleinopathies, including Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA), is challenging due to overlapping clinical features and the current lack of reliable biomarkers. The primary diagnostic approach remains clinical, underscoring the need for objective biomarkers that can distinguish between these diseases. This study profiles α-synuclein peptides in plasma to explore potential disease-specific patterns. Methods: We developed a targeted mass spectrometry-based assay to profile α-synuclein in plasma samples from PD (n=82), DLB (n=32), MSA (n=8), and controls (n=21). The assay quantifies non-modified peptides specifically derived from the N-terminus and NAC domain, regions implicated in aggregate formation, to assess potential disease-specific peptide patterns. Results: No significant differences in peptide levels were observed between the disease groups, indicating consistent N-terminus and NAC domain profiles among α-synucleinopathies. However, a peptide within the NAC domain showed distinct patterns in MSA compared to other groups, which may reflect unique pathological processes. Conclusions: This study provides the first blood-based assessment of α-synuclein peptide profiles, establishing a basis for future research into α-synucleinopathies. Refining the assay to include post-translationally modified peptides may enhance understanding of disease mechanisms and improve biomarker development.

Plasma α-synuclein domain profiles across α-synucleinopathies